Omadacycline

Drug Profile

Omadacycline

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; PTK-0796; PTK796

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Merck & Co; Paratek Pharmaceuticals
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; Skin and soft tissue infections
  • Phase I Nosocomial infections; Urinary tract infections
  • Preclinical Acute sinusitis
  • Research Anthrax; Plague

Most Recent Events

  • 18 Jan 2017 Paratek completes enrolment in a Phase-III clinical trials for Community-acquired pneumonia in USA, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Latvia, Slovakia, Spain, Belgium, Israel, South Korea, South Africa, Taiwan, Ukraine and Poland
  • 02 Nov 2016 Pharmacokinetics data from a phase Ib trial in Urinary tract infection released by Paratek Pharmaceuticals
  • 02 Nov 2016 Paratek Pharmaceuticals completes a phase Ib trial in Urinary tract infection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top